Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Oncology · Breast Cancer

How Is an Axillary-Tail Tumor Staged in Breast Cancer?

At a Glance

An axillary-tail tumor confirmed to begin in breast or accessory breast tissue is staged as primary breast cancer, not as cancer in a lymph node. Doctors use the invasive tumor size, lymph-node findings, distant spread, and tumor biology to determine the overall stage.

Finding a lump in your armpit (axilla) can understandably be alarming. However, if your medical team confirms that your tumor started in the axillary tail, it is staged as a primary breast cancer, not as lymph node cancer. The axillary tail is an extension of normal breast tissue that reaches up into the armpit area. Just because a tumor is located in this region does not automatically mean that it is a lymph node containing cancer, or that the cancer has spread.

The Axillary Tail vs. Axillary Lymph Nodes

The axillary tail of Spence is a band of normal breast tissue that extends from the upper-outer quadrant of the breast into the armpit. Some people also have accessory breast tissue (ectopic tissue), which consists of small, separate amounts of normal breast tissue located in the armpit [1].

Also located nearby in the armpit are axillary lymph nodes—small, bean-shaped organs that act as immune system filters. Because breast tissue and lymph nodes share this exact physical space, it requires careful evaluation to determine whether an armpit mass is a new breast tumor or cancer that has spread to a lymph node [2].

How an Axillary-Tail Tumor is Staged

When a tumor is confirmed to have originated in the axillary tail or accessory breast tissue, it is staged as a primary breast cancer using the standard TNM staging system [3]. Even though cancer registries might note the axillary tail as a distinct location, it is treated as a breast primary [4][5].

  • Tumor (T): The T category is generally based on the greatest dimension of the invasive component of the tumor in the breast tissue [3].
  • Node (N): The N category assesses whether cancer has spread to your actual regional lymph nodes. A tumor’s location in the axillary tail alone does not make you node-positive [2][6]. Your node status requires a separate evaluation.
  • Metastasis (M): The M category indicates whether the cancer has spread to distant parts of the body.

Clinical, Pathological, and Prognostic Staging
Your doctor may give you a clinical stage based on initial imaging and physical exams. This may be updated to a pathological stage after surgery when the entire tumor and sampled lymph nodes are examined under a microscope. Additionally, your prognostic stage will incorporate tumor biology—such as tumor grade and hormone receptor status (ER, PR, and HER2)—to better predict your outlook and guide treatment [7][8].

How Doctors Tell the Difference

Because the axillary tail and lymph nodes are adjacent, distinguishing between them requires a combination of imaging and tissue sampling.

Imaging
Ultrasound and MRI are often used to evaluate an armpit mass. A healthy lymph node typically looks like a kidney bean with a distinct fatty center (called a hilum) and a thin outer layer [9][10]. If a lymph node becomes round, the outer layer thickens, or the fatty center is lost, it may raise suspicion that cancer has spread to that node [9][11]. However, inflammation can also cause these changes, and some metastatic nodes can look normal. Therefore, imaging alone is not definitive, and an image-guided biopsy is often needed.

Biopsy and Pathology
Looking at a tissue sample under a microscope provides crucial clues about where the tumor started.

  • Signs Favoring a Breast Primary: A pathologist will look for normal breast ducts, surrounding benign breast glands, or ductal carcinoma in situ (DCIS) [1][12]. DCIS refers to cancer cells confined inside milk ducts. Finding these features strongly supports that the tumor originated in breast tissue [13].
  • Signs Favoring a Lymph Node: The pathologist will also look for lymphoid (immune) tissue. While an absence of lymphoid tissue in the sample can support the diagnosis of an axillary tail tumor [1], it is not absolute proof. A small core needle biopsy might simply miss the lymphoid tissue, or a tumor might have completely replaced a node’s normal structure. The pathologist will evaluate the tissue alongside your imaging results to make a final determination.

Common questions in this guide

Is a tumor in the axillary tail considered breast cancer or lymph-node cancer?
If testing confirms that the tumor began in breast tissue in the axillary tail or in accessory breast tissue, it is classified and staged as a primary breast cancer. Its location near the armpit does not by itself mean that it started in a lymph node or has spread to one.
Does an axillary-tail tumor automatically mean I have positive lymph nodes?
No. The N category is based on whether cancer is found in regional lymph nodes, which must be assessed separately from the primary tumor’s location. Imaging, a node biopsy, or examination of sampled nodes may be used as appropriate.
How does the tumor’s size affect its breast cancer stage?
For a tumor that began in breast tissue, the T category is generally based on the greatest dimension of its invasive component. The size is considered with lymph-node findings, distant spread, and other tumor features to determine the overall stage.
What tests distinguish an axillary-tail tumor from cancer in a lymph node?
Ultrasound or MRI can show features that suggest a lymph node or a mass in breast tissue, but imaging alone cannot make the distinction with certainty. A biopsy lets the pathologist look for normal breast ducts, benign breast glands, DCIS, or lymphoid tissue and interpret those findings with the imaging.
What is the difference between clinical, pathological, and prognostic stage?
Clinical stage uses the examination and imaging available before treatment. Pathological stage is based on the tumor and sampled lymph nodes examined after surgery, while prognostic stage also considers features such as grade and ER, PR, and HER2 status.
Why does DCIS matter in a biopsy from the armpit area?
DCIS is cancer cells confined inside milk ducts. Finding DCIS or normal breast ducts around the tumor supports that the mass began in breast tissue rather than in an axillary lymph node, although the pathologist considers all tissue and imaging findings together.

Get notified when new evidence is published on female breast upper-outer quadrant cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (13)
  1. 1

    Carcinoma of the Accessory Axillary Breast: A Diagnostic Dilemma and a Management Challenge.

    Sinduja R, Kumaran R, Sundaramurthi S, et al.

    Cureus 2020; (12(12)):e11844 doi:10.7759/cureus.11844.

    PMID: 33409083
  2. 2

    Carcinoma of the axillary tail of Spence: A rare case report.

    Kalita P, Gupta A, Sengupta P, et al.

    International journal of surgery case reports 2024; (114()):109151 doi:10.1016/j.ijscr.2023.109151.

    PMID: 38096700
  3. 3

    A Survey of Breast Pathologists' Practice in Staging Multiple Foci of Invasive Carcinoma.

    Wu JM, Turashvili G

    Clinical breast cancer 2021; (21(5)):e506-e511 doi:10.1016/j.clbc.2020.11.018.

    PMID: 33386230
  4. 4

    Tumor Site and Breast Cancer Prognosis.

    Siotos C, McColl M, Psoter K, et al.

    Clinical breast cancer 2018; (18(5)):e1045-e1052 doi:10.1016/j.clbc.2018.05.007.

    PMID: 29941391
  5. 5

    Decreased survival in patients with carcinoma of axillary tail versus upper outer quadrant breast cancers: a SEER population-based study.

    Gou ZC, Liu XY, Xiao Y, et al.

    Cancer management and research 2018; (10()):1133-1141 doi:10.2147/CMAR.S165291.

    PMID: 29795985
  6. 6

    Accessory breast cancer in the inframammary region: a case report and review of the literature.

    Eguchi Y, Yoshinaka H, Hayashi N, et al.

    Surgical case reports 2021; (7(1)):203 doi:10.1186/s40792-021-01285-6.

    PMID: 34495428
  7. 7

    Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

    Giuliano AE, Connolly JL, Edge SB, et al.

    CA: a cancer journal for clinicians 2017; (67(4)):290-303 doi:10.3322/caac.21393.

    PMID: 28294295
  8. 8

    Breast Cancer Staging: Updates in the AJCC Cancer Staging Manual, 8th Edition, and Current Challenges for Radiologists, From the AJR Special Series on Cancer Staging.

    Teichgraeber DC, Guirguis MS, Whitman GJ

    AJR. American journal of roentgenology 2021; (217(2)):278-290 doi:10.2214/AJR.20.25223.

    PMID: 33594908
  9. 9

    Lymph Node Imaging in Patients with Primary Breast Cancer: Concurrent Diagnostic Tools.

    Marino MA, Avendano D, Zapata P, et al.

    The oncologist 2020; (25(2)):e231-e242 doi:10.1634/theoncologist.2019-0427.

    PMID: 32043792
  10. 10

    Assessment of Ultrasound Features Predicting Axillary Nodal Metastasis in Breast Cancer: The Impact of Cortical Thickness.

    Stachs A, Thi AT, Dieterich M, et al.

    Ultrasound international open 2015; (1(1)):E19-24 doi:10.1055/s-0035-1555872.

    PMID: 27689144
  11. 11

    Preoperative Evaluation of Axillary Lymph Nodes in Malignant Breast Lesions with Ultrasonography and Histopathologic Correlation.

    Fidan N, Ozturk E, Yucesoy C, Hekimoglu B

    Journal of the Belgian Society of Radiology 2016; (100(1)):58 doi:10.5334/jbr-btr.899.

    PMID: 30038983
  12. 12

    Axillary Reverse Lymphatic Mapping in the Treatment of Axillary Accessory Breast Cancer: A Case Report and Review of Management.

    Friedman-Eldar O, Melnikau S, Tjendra Y, Avisar E

    European journal of breast health 2022; (18(1)):1-5 doi:10.4274/ejbh.galenos.2021.2021-7-3.

    PMID: 35059584
  13. 13

    [One Case of Accessory Breast Cancer Complicated by Contralateral Breast Cancer].

    Shinseki K, Takahashi M, Kushima A, et al.

    Gan to kagaku ryoho. Cancer & chemotherapy 2020; (47(12)):1703-1705.

    PMID: 33342987

This page is for informational purposes only and does not constitute medical advice. Your breast team should interpret your imaging, pathology, and TNM stage in the context of your care.